Phanes Therapeutics is a San Diego, CA and Shanghai, China-based company that specializes in innovative drug discovery in immuno-oncology. Led by Ming Wang, PhD/MBA, CEO, the company focuses on discovery and development of innovative biologic drugs for oncology and eye diseases. Its research programs include projects in the PACbody™ and ATACCbody™ platforms. In May 2021 Phanes raised $40M in a Series B funding round led by Sequoia Capital China, with participation from new investors and current shareholders. The company intends to use the funds to advance several preclinical programs to the clinic, expand its research and clinical teams, and support advancement of research projects in its platforms. The article did not report revenue, user numbers, or other operating metrics.

Total raised

$40M

Funding rounds

1

Latest round

Series B

Latest activity

May 2021